Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. / Meier, Juris J; Nauck, Michael A; Pott, Andrea; Heinze, Kai; Goetze, Oliver; Bulut, Kerem; Schmidt, Wolfgang E; Gallwitz, Baptist; Holst, Jens Juul.

In: Gastroenterology, Vol. 130, No. 1, 01.2006, p. 44-54.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Meier, JJ, Nauck, MA, Pott, A, Heinze, K, Goetze, O, Bulut, K, Schmidt, WE, Gallwitz, B & Holst, JJ 2006, 'Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans', Gastroenterology, vol. 130, no. 1, pp. 44-54. https://doi.org/10.1053/j.gastro.2005.10.004

APA

Meier, J. J., Nauck, M. A., Pott, A., Heinze, K., Goetze, O., Bulut, K., Schmidt, W. E., Gallwitz, B., & Holst, J. J. (2006). Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology, 130(1), 44-54. https://doi.org/10.1053/j.gastro.2005.10.004

Vancouver

Meier JJ, Nauck MA, Pott A, Heinze K, Goetze O, Bulut K et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology. 2006 Jan;130(1):44-54. https://doi.org/10.1053/j.gastro.2005.10.004

Author

Meier, Juris J ; Nauck, Michael A ; Pott, Andrea ; Heinze, Kai ; Goetze, Oliver ; Bulut, Kerem ; Schmidt, Wolfgang E ; Gallwitz, Baptist ; Holst, Jens Juul. / Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. In: Gastroenterology. 2006 ; Vol. 130, No. 1. pp. 44-54.

Bibtex

@article{5eb631bdd83e48d9a8ac6c865c707110,
title = "Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans",
abstract = "BACKGROUND & AIMS: The gut-derived peptide glucagon-like peptide 2 (GLP-2) has been suggested as a potential drug candidate for the treatment of various intestinal diseases. However, the acute effects of GLP-2 on gastric functions as well as on glucose and lipid homeostasis in humans are less well characterized.METHODS: Fifteen healthy male volunteers were studied with the intravenous infusion of GLP-2 or placebo over 120 minutes in the fasting state, and pentagastrin-stimulated gastric acid output was assessed. Another 15 healthy male volunteers were studied with a 390 minutes infusion of GLP-2 or placebo during the ingestion of a solid test meal. Gastric emptying was determined using a 13C-sodium-octanote breath test. Plasma concentrations of glucose, insulin, C-peptide, glucagon, GLP-2, free fatty acids, free glycerol, and triglycerides were determined.RESULTS: GLP-2 administration led to a marked increase in glucagon concentrations both in the fasting state and during the meal study (P < .001). Postprandial plasma concentrations of triglycerides and free fatty acids were significantly higher during GLP-2 infusion compared with placebo (P < .01), while glycerol concentrations were similar (P = .07). GLP-2 administration caused an approximately 15% reduction in pentagastrin-stimulated gastric acid and chloride secretion (P < .01), whereas gastric emptying was not affected (P = .99).CONCLUSIONS: GLP-2 reduces gastric acid secretion but does not seem to have an influence on gastric emptying. The stimulation of glucagon secretion by GLP-2 may counteract the glucagonostatic effect of GLP-1. Changes in postprandial lipid excursions seem to reflect enhanced intestinal nutrient absorption during GLP-2 administration.",
keywords = "Adult, Fasting, Fatty Acids, Gastric Acid, Gastric Emptying, Glucagon, Glucagon-Like Peptide 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Infusions, Intravenous, Insulin, Lipid Metabolism, Male, Placebos, Postprandial Period",
author = "Meier, {Juris J} and Nauck, {Michael A} and Andrea Pott and Kai Heinze and Oliver Goetze and Kerem Bulut and Schmidt, {Wolfgang E} and Baptist Gallwitz and Holst, {Jens Juul}",
year = "2006",
month = jan,
doi = "10.1053/j.gastro.2005.10.004",
language = "English",
volume = "130",
pages = "44--54",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "Elsevier",
number = "1",

}

RIS

TY - JOUR

T1 - Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans

AU - Meier, Juris J

AU - Nauck, Michael A

AU - Pott, Andrea

AU - Heinze, Kai

AU - Goetze, Oliver

AU - Bulut, Kerem

AU - Schmidt, Wolfgang E

AU - Gallwitz, Baptist

AU - Holst, Jens Juul

PY - 2006/1

Y1 - 2006/1

N2 - BACKGROUND & AIMS: The gut-derived peptide glucagon-like peptide 2 (GLP-2) has been suggested as a potential drug candidate for the treatment of various intestinal diseases. However, the acute effects of GLP-2 on gastric functions as well as on glucose and lipid homeostasis in humans are less well characterized.METHODS: Fifteen healthy male volunteers were studied with the intravenous infusion of GLP-2 or placebo over 120 minutes in the fasting state, and pentagastrin-stimulated gastric acid output was assessed. Another 15 healthy male volunteers were studied with a 390 minutes infusion of GLP-2 or placebo during the ingestion of a solid test meal. Gastric emptying was determined using a 13C-sodium-octanote breath test. Plasma concentrations of glucose, insulin, C-peptide, glucagon, GLP-2, free fatty acids, free glycerol, and triglycerides were determined.RESULTS: GLP-2 administration led to a marked increase in glucagon concentrations both in the fasting state and during the meal study (P < .001). Postprandial plasma concentrations of triglycerides and free fatty acids were significantly higher during GLP-2 infusion compared with placebo (P < .01), while glycerol concentrations were similar (P = .07). GLP-2 administration caused an approximately 15% reduction in pentagastrin-stimulated gastric acid and chloride secretion (P < .01), whereas gastric emptying was not affected (P = .99).CONCLUSIONS: GLP-2 reduces gastric acid secretion but does not seem to have an influence on gastric emptying. The stimulation of glucagon secretion by GLP-2 may counteract the glucagonostatic effect of GLP-1. Changes in postprandial lipid excursions seem to reflect enhanced intestinal nutrient absorption during GLP-2 administration.

AB - BACKGROUND & AIMS: The gut-derived peptide glucagon-like peptide 2 (GLP-2) has been suggested as a potential drug candidate for the treatment of various intestinal diseases. However, the acute effects of GLP-2 on gastric functions as well as on glucose and lipid homeostasis in humans are less well characterized.METHODS: Fifteen healthy male volunteers were studied with the intravenous infusion of GLP-2 or placebo over 120 minutes in the fasting state, and pentagastrin-stimulated gastric acid output was assessed. Another 15 healthy male volunteers were studied with a 390 minutes infusion of GLP-2 or placebo during the ingestion of a solid test meal. Gastric emptying was determined using a 13C-sodium-octanote breath test. Plasma concentrations of glucose, insulin, C-peptide, glucagon, GLP-2, free fatty acids, free glycerol, and triglycerides were determined.RESULTS: GLP-2 administration led to a marked increase in glucagon concentrations both in the fasting state and during the meal study (P < .001). Postprandial plasma concentrations of triglycerides and free fatty acids were significantly higher during GLP-2 infusion compared with placebo (P < .01), while glycerol concentrations were similar (P = .07). GLP-2 administration caused an approximately 15% reduction in pentagastrin-stimulated gastric acid and chloride secretion (P < .01), whereas gastric emptying was not affected (P = .99).CONCLUSIONS: GLP-2 reduces gastric acid secretion but does not seem to have an influence on gastric emptying. The stimulation of glucagon secretion by GLP-2 may counteract the glucagonostatic effect of GLP-1. Changes in postprandial lipid excursions seem to reflect enhanced intestinal nutrient absorption during GLP-2 administration.

KW - Adult

KW - Fasting

KW - Fatty Acids

KW - Gastric Acid

KW - Gastric Emptying

KW - Glucagon

KW - Glucagon-Like Peptide 2

KW - Glucagon-Like Peptides

KW - Humans

KW - Hypoglycemic Agents

KW - Infusions, Intravenous

KW - Insulin

KW - Lipid Metabolism

KW - Male

KW - Placebos

KW - Postprandial Period

U2 - 10.1053/j.gastro.2005.10.004

DO - 10.1053/j.gastro.2005.10.004

M3 - Journal article

C2 - 16401467

VL - 130

SP - 44

EP - 54

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 1

ER -

ID: 132053274